Immunome Appoints Jean-Jacques Bienaimé to Board of Directors

Rhea-AI Summary

IMNM: Immunome Appoints Jean-Jacques 'JJ' Bienaimé to Board of Directors, an Accomplished Biotech and Pharma Executive with Over 30 Years of Experience, Former CEO of BioMarin Pharmaceuticals

Positive

• Jean-Jacques Bienaimé's extensive experience in the biotech and pharma industries, including growing BioMarin Pharmaceuticals from a $400 million to a $15 billion company, adds valuable expertise to Immunome's Board of Directors.
• Mr. Bienaimé's patient-centric approach and operational excellence align with Immunome's commitment to developing first-in-class and best-in-class targeted cancer therapies, enhancing the company's potential for growth and success.

Negative

• None.

- Accomplished biotechnology and pharmaceutical executive with over three decades of experience to join Immunome’s Board of Directors -

SEATTLE & EXTON, Pa.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the biotechnology and pharmaceutical industries, most recently serving as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals.

“Immunome is pleased to welcome JJ to the Board of Directors as we enter our next stage of growth,” stated Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “JJ has a unique understanding of how to build a biotechnology company, and he shares our commitment to improving the lives of cancer patients. His guidance will be essential as we advance our pipeline of potential first-in-class and best-in-class targeted cancer therapies.”

“I am excited to join the Immunome Board of Directors as they work to bring transformative oncology therapeutics to the patients most in need,” commented Mr. Bienaimé. “Throughout my career, pairing a patient-centric approach with operational excellence has been foundational to success, and I see that same mentality at Immunome. I look forward to enhancing Immunome’s ability to execute on Clay’s compelling vision.”

Mr. Bienaimé currently serves as Chairman and Chief Executive Officer of BioMarin Pharmaceuticals, Inc., a position that he has held since 2005. Under Mr. Bienaimé’s leadership, BioMarin grew from a company with a single marketed treatment product to a multi-billion-dollar commercial organization with numerous approved products to treat rare diseases, increasing the company’s value from approximately $400 million to approximately $15 billion. It has been announced that Mr. Bienaimé will transition to retirement from his role as Chairman and Chief Executive Officer of BioMarin effective December 1, 2023. Prior to joining BioMarin, Mr. Bienaimé served as the Chairman, President and Chief Executive Officer of Genencor, a targeted oncology biopharmaceutical company that was ultimately acquired in 2005 by Danisco. Prior to Genencor, Mr. Bienaimé held the positions of Chairman, President and Chief Executive Officer of Sangstat Medical. During his time at Sangstat Medical, Mr. Bienaimé guided the company to profitability, prior to an eventual acquisition by Genzyme. Prior to joining Sangstat Medical, Mr. Bienaimé held various senior management positions at Rhone-Poulenc Rorer Pharmaceuticals and Genentech.

Mr. Bienaimé currently serves on the Board of Directors of Incyte Corp., a biopharmaceutical company focused on first-in-class treatments for serious unmet needs, the Pharmaceutical Research and Manufacturers of America organization (PhMRA) and The Biotech Industry Organization (BIO). Mr. Bienaimé received his MBA from the Wharton School at the University of Pennsylvania and his undergraduate degree from the École Supérieure de Commerce de Paris.

About Immunome, Inc.

Immunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, targeted effectors, radioligand therapies and ADCs. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.

For more information, visit www.immunome.com or follow us on Twitter and LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this communication regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). These include, but are not limited to, statements regarding Immunome’s intent to advance its current pipeline into the clinic, to develop first-in-class and best-in-class targeted cancer therapies for patients; to bring transformative oncology therapeutics to the patients most in need; and other statements regarding management’s intentions, plans, beliefs, expectations or forecasts for the future. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Immunome undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. We use words such as “expect,” “look forward to,” “goal,” “will,” and other similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, the ability of Immunome to grow and successfully execute on its business plan, including advancing its current pipeline into the clinic and expanding its pipeline through its technology platform, proprietary toolbox as and when anticipated, and through strategic transactions, if any; changes in the applicable laws or regulations; the possibility that Immunome may be adversely affected by other economic, business, and/or competitive factors; the risk that regulatory approvals for Immunome’s programs and product candidates are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect it; Immunome’s ability to manage clinical trials or studies; the risk that pre-clinical data may not be predictive of clinical data; the complexity of numerous regulatory and legal requirements that Immunome needs to comply with to operate its business; the reliance on Immunome’s management and board members and the fact that the prior experience and successes of the Immunome’s management team and board members are not indicative of any future success for Immunome; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; the failure to obtain, adequately protect, maintain or enforce Immunome’s intellectual property rights; and other risks and uncertainties indicated from time to time described in Immunome’s Annual Report on Form 10-K for the year ended December 31, 2022, and in Immunome’s other filings with the SEC. Immunome cautions that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements which speak only as of the date made. Moreover, Immunome operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Except as required by law, Immunome does not undertake any obligation to update publicly any forward-looking statements for any reason after the date of this press release to conform these statements to actual results or to changes in their expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108166623/en/

Investor Contact

Corleen Roche

Chief Financial Officer

investors@immunome.com

Media Contact

Andrew W. Mielach

LifeSci Communications

amielach@lifescicomms.com

Source: Immunome, Inc.

FAQ

Who is joining Immunome's Board of Directors?

Jean-Jacques 'JJ' Bienaimé, an experienced biotech and pharma executive, and former CEO of BioMarin Pharmaceuticals.

What is Immunome focused on developing?

Immunome is focused on developing first-in-class and best-in-class targeted cancer therapies.

What is Jean-Jacques Bienaimé's background?

Mr. Bienaimé has over three decades of experience in the biotech and pharma industries, most recently serving as Chairman and CEO of BioMarin Pharmaceuticals.

What is Jean-Jacques Bienaimé's impact on BioMarin Pharmaceuticals?

Under Mr. Bienaimé’s leadership, BioMarin grew from a $400 million to a $15 billion company.

What are some of the companies Mr. Bienaimé has been associated with?

Mr. Bienaimé has held leadership positions at Genencor, Sangstat Medical, Rhone-Poulenc Rorer Pharmaceuticals, and Genentech.